ECSP21000308A - Anticuerpos contra agentes patógenos en acuacultura y sus aplicaciones - Google Patents

Anticuerpos contra agentes patógenos en acuacultura y sus aplicaciones

Info

Publication number
ECSP21000308A
ECSP21000308A ECSENADI2021308A ECDI202100308A ECSP21000308A EC SP21000308 A ECSP21000308 A EC SP21000308A EC SENADI2021308 A ECSENADI2021308 A EC SENADI2021308A EC DI202100308 A ECDI202100308 A EC DI202100308A EC SP21000308 A ECSP21000308 A EC SP21000308A
Authority
EC
Ecuador
Prior art keywords
aquaculture
applications
antibodies against
against pathogenic
pathogenic agents
Prior art date
Application number
ECSENADI2021308A
Other languages
English (en)
Inventor
Petegem Filip Louis Van
Tsz Ying Cheung
Slade Loutet
Hamlet Abnousi
Original Assignee
Novobind Livestock Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novobind Livestock Therapeutics Inc filed Critical Novobind Livestock Therapeutics Inc
Publication of ECSP21000308A publication Critical patent/ECSP21000308A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1239—Gram-negative bacteria from Vibrionaceae (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen aquí los métodos y anticuerpos efectivos para reducir, eliminar o prevenir la infección de una población bacteriana o viral en un animal acuático. También se describen aquí los antígenos efectivos para reducir una población bacteriana o viral en un animal acuático empleando anticuerpos de cadena pesada y fragmentos de VHH.
ECSENADI2021308A 2018-06-05 2021-01-05 Anticuerpos contra agentes patógenos en acuacultura y sus aplicaciones ECSP21000308A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862680736P 2018-06-05 2018-06-05

Publications (1)

Publication Number Publication Date
ECSP21000308A true ECSP21000308A (es) 2021-06-30

Family

ID=69059691

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI2021308A ECSP21000308A (es) 2018-06-05 2021-01-05 Anticuerpos contra agentes patógenos en acuacultura y sus aplicaciones

Country Status (9)

Country Link
US (1) US20220119506A1 (es)
EP (1) EP3802592A4 (es)
CN (1) CN112566932A (es)
BR (1) BR112020024878A2 (es)
CA (1) CA3102039A1 (es)
EC (1) ECSP21000308A (es)
IL (1) IL279117A (es)
MX (1) MX2020013248A (es)
WO (1) WO2020008254A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11130800B2 (en) 2016-05-20 2021-09-28 Novobind Livestock Therapeutics Inc. Antibodies against microorganisms and uses thereof
CA3118819A1 (en) 2018-11-13 2020-05-22 Novobind Livestock Therapeutics Inc. Antibodies against disease causing agents of canines and felines and uses thereof
CN114980750A (zh) * 2019-09-05 2022-08-30 美国卵石实验室公司 用于抑制细菌毒素以治疗水生动物早期死亡综合征的系统、方法和组合物
KR102550527B1 (ko) * 2020-11-27 2023-07-03 주식회사 엔바이로젠 흰반점증후군 바이러스에 특이적인 재조합 항체 및 이의 용도
CN115181731B (zh) * 2021-04-02 2023-12-15 青岛诺安百特生物技术有限公司 一株坎贝氏弧菌噬菌体、制备方法及其应用
WO2023104933A1 (en) * 2021-12-07 2023-06-15 new/era/mabs GmbH Camelid antibodies for use in therapy and diagnosis
WO2024092360A1 (en) * 2022-11-03 2024-05-10 Novobind Livestock Therapeutics Inc. Antibodies against aquaculture disease-causing agents and uses thereof
CN116130025A (zh) * 2022-12-12 2023-05-16 中国科学院南海海洋研究所 一种致病弧菌Pir B毒力蛋白结合肽P2及其应用
CN120119012A (zh) * 2025-03-10 2025-06-10 汕尾市海洋产业研究院 一种用于检测栖黑海弧菌的引物探针组、试剂盒及方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02004861A (es) * 2000-09-15 2003-05-23 Akzo Nobel Nv Proteinas antigenicas de virus de sindrome de mancha blanca de camaron y uso de las mismas.
KR20030069506A (ko) * 2002-02-21 2003-08-27 주식회사 리앤조바이오텍 새우 흰 반점 바이러스에 대한 난황항체
EP1900753B1 (en) * 2002-11-08 2017-08-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
AU2006323415A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
EP2328929A2 (en) * 2008-09-10 2011-06-08 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
CN101691403B (zh) * 2009-08-03 2011-11-09 中国海洋大学 抗对虾白斑症病毒囊膜蛋白vp28独特型单克隆抗体及其制备方法
DE102011121238A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-antikörper gegen clostridium difficile toxine
MY199990A (en) * 2014-03-27 2023-12-02 Sambuddha Ghosh Expression of a single chain antibody against salmonella in lactobacillus
US11130800B2 (en) * 2016-05-20 2021-09-28 Novobind Livestock Therapeutics Inc. Antibodies against microorganisms and uses thereof

Also Published As

Publication number Publication date
MX2020013248A (es) 2021-04-13
IL279117A (en) 2021-01-31
EP3802592A1 (en) 2021-04-14
US20220119506A1 (en) 2022-04-21
CA3102039A1 (en) 2020-01-09
EP3802592A4 (en) 2022-06-15
CN112566932A (zh) 2021-03-26
WO2020008254A1 (en) 2020-01-09
BR112020024878A2 (pt) 2021-03-09

Similar Documents

Publication Publication Date Title
ECSP21000308A (es) Anticuerpos contra agentes patógenos en acuacultura y sus aplicaciones
PH12021550025A1 (en) Antibodies against disease causing agents of poultry and uses thereof
UY38215A (es) Métodos y composiciones para matar una bacteria de interés
ECSP21000695A (es) Anticuerpos dirigidos contra il-11
PH12021552921A1 (en) Antibodies against disease causing agents of poultry and uses thereof
CY1122179T1 (el) Μεθοδοι και συνθεσεις για την παραγωγη ή την διατηρηση πολυδυναμων κυτταρων
CL2020003218A1 (es) Anticuerpos dirigidos contra il-11ra
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
MX2020010227A (es) Construcciones dirigidas a cd22 y usos de las mismas.
CL2017002433A1 (es) Una nueva forma de il33, formas mutadas de il33, anticuerpos, ensayos y métodos para usar los mismos
EA202092202A1 (ru) Конструкции антител к ror
CR20170139A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
ECSP21068097A (es) Anticuerpos claudina 6 y usos de los mismos
CL2023001052A1 (es) Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
CY1125009T1 (el) Προβιοτικα βακτηριδια για ιχθεις
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
CR20200404A (es) Anticuerpos anti-klk5 y métodos de uso
CL2019000664A1 (es) Sistema paratransgénico novedoso para el control de mosquitos que transmiten enfermedades.
ECSP20016817A (es) Sistemas y métodos para el control de la enfermedad de necrosis hepatopancreática aguda
EA201992278A1 (ru) Способы и композиции для снижения иммуногенности
CO2020006907A2 (es) Péptidos antimicrobianos y métodos para usarlos
CL2019001275A1 (es) Atenuación de virulencia bacteriana mediante atenuación de transporte de folato bacteriano.
AR105541A1 (es) ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR VRSh
CL2020001816A1 (es) Bacterias probióticas para peces.
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.